Download DNB 2017 Dec HEMAT HEMAT Paper I Question Paper

Download Diplomate in National Board (DNB) 2017 Dec HEMAT HEMAT Paper I Previous Question Papers

FINAL EXAM www. F i rstRan kendb?ONAL BOWWK? r.com
DECEMBER 2017
HEMATOLOGY
PAPER-l
HEM/D/17/48/l
Time: 3 hours
Max. Marks: 100
Attempt all questions in order.
Each question carries 10 marks.
Read the question carefully and answer to the point neatly and legibly.
Do not leave any blank pages between two answers.
Indicate the question number correctly for the answer in the margin space
Answer all the parts of a single question together.
Start the question to a question on a fresh page or leave adequate space between two answers.
Draw table/diagrams/?owcharts wherever appropriate.
Write short notes on:
1. a) Vitamin B12 metabolism 4+3+3
b) Role of Vitamin B12 levels in diagnosis of B12
deficiency and pitfalls
0) Clinical manifestations of vitamin B12 deficiency
d) Non?megaloblastic macrocytic anemia and its causes
2. Hemophilia: 3+4+3
a) Causes of acquired hemophilia
b) Eliciting joint abnormalities
0) Prenatal diagnosis of hemophilia
3. Angiogenesis: 3+4+3
a) Its role in hematologic malignancies
b) Anti-angiogenic drugs in treatment of hematologic
malignancies
c) Markers of angiogenesis
4. AML: 4+3+3
a) Molecular markers affecting prognosis of AML
b) FLT3 Inhibitors
c) AML with related myelodysplasia
5. CART cells in Pediatric ALL: 4+3+3
a) Role of therapy in Pediatric ALL
b) How are they formed?
0) What lab facilities are required for generating and
using CART cells in patients?
6. Autoimmune hemolytic anemia (AIHA): 4+3+3
a) Management of warm type of AIHA.
b) Methods of detection of auto?antibodies against RBC
0) Coomb?s negative auto immune hemolytic anemia
1
.1.
POSSESSION/USE OF CELL PHONES OR ANY S UCH ELECTISONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
www.FIrstRanker.com

FINAL EXAM www.FirstRanker.cl?d>??;i0NAL BOWWK?Lcom
DECEMBER 2017
7. a) Compensation in clinicaltrials 4+3+3
b) Role of sponsors in clinical trial
0) Salient features of Phase I, II and III clinical trials.
8. a) Growth factors in normal hematopoiesis 3+4+3
b) Microenvironment in acquired aplastic anemia
c) Hematopoietic stem cell
9. Minimal residual disease in ALL: 3+4+3
a) What is minimal residual disease?
b) How is it detected?
0) How does treatment alter based on MRD?
10. a) What are T-reg cells and how are they picked up? 4+3+3
) What is their role in ITP?
0) Describe in brief dendritic cells
*****
?3
.5.
POSSESSION/USE OF CELL PHONES OR ANY S UCH ELECTISONIC GADGETS IS NOT PERMITTED INSIDE THE EXAMINATION HALL.
www.FIrstRanker.com